Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit

Bill Carroll

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

BackgroundThe therapeutic goal for multiple sclerosis (MS) is to achieve a better long-term outcome. However, since available data come from short-term studies, it is important to review the evidence that current therapies provide long-term benefit.Method and resultsLong-term data from both registry studies and long-term follow-up studies, and efficacy treatment data were reviewed. Registry data show that the course of MS is predictable after a certain level of disability is reached, indicating that short-term efficacy data from randomized, controlled trials provide evidence of long-term benefit. Long-term studies of patients originally enrolled in pivotal randomized, controlled trials consistently show that delayed or discontinued treatment provides less benefit than continuous therapy. The 16-Year Long-Term Follow-Up Study of interferon beta-1b (IFNβ-1b; Betaferon®/Betaseron®) therapy had the highest ascertainment of long-term follow-up efforts of the pivotal trials, which led to the currently approved therapies. Disability scores at the start of treatment were predictive of their current disability scores. In addition, this 16-year study showed an excellent safety profile with no unexpected side effects to IFNβ-1b and a lower mortality rate after 16 years compared with those receiving placebo treatment during the pivotal study (6 deaths vs 20 deaths).ConclusionThis article reviews the key data and provides recommendations for optimizing clinical studies in MS to demonstrate long-term patient benefit.
Original languageEnglish
Pages (from-to)951-958
JournalMultiple Sclerosis
Volume15
Issue number8
DOIs
Publication statusPublished - 2009

Fingerprint

Multiple Sclerosis
Clinical Trials
Therapeutics
Registries
Randomized Controlled Trials
Placebos
Safety
Mortality
Interferon beta-1b

Cite this

@article{53e20328e0f64236b6f848f8b51a6a43,
title = "Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit",
abstract = "BackgroundThe therapeutic goal for multiple sclerosis (MS) is to achieve a better long-term outcome. However, since available data come from short-term studies, it is important to review the evidence that current therapies provide long-term benefit.Method and resultsLong-term data from both registry studies and long-term follow-up studies, and efficacy treatment data were reviewed. Registry data show that the course of MS is predictable after a certain level of disability is reached, indicating that short-term efficacy data from randomized, controlled trials provide evidence of long-term benefit. Long-term studies of patients originally enrolled in pivotal randomized, controlled trials consistently show that delayed or discontinued treatment provides less benefit than continuous therapy. The 16-Year Long-Term Follow-Up Study of interferon beta-1b (IFNβ-1b; Betaferon{\circledR}/Betaseron{\circledR}) therapy had the highest ascertainment of long-term follow-up efforts of the pivotal trials, which led to the currently approved therapies. Disability scores at the start of treatment were predictive of their current disability scores. In addition, this 16-year study showed an excellent safety profile with no unexpected side effects to IFNβ-1b and a lower mortality rate after 16 years compared with those receiving placebo treatment during the pivotal study (6 deaths vs 20 deaths).ConclusionThis article reviews the key data and provides recommendations for optimizing clinical studies in MS to demonstrate long-term patient benefit.",
author = "Bill Carroll",
year = "2009",
doi = "10.1177/1352458509105426",
language = "English",
volume = "15",
pages = "951--958",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "8",

}

Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit. / Carroll, Bill.

In: Multiple Sclerosis, Vol. 15, No. 8, 2009, p. 951-958.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit

AU - Carroll, Bill

PY - 2009

Y1 - 2009

N2 - BackgroundThe therapeutic goal for multiple sclerosis (MS) is to achieve a better long-term outcome. However, since available data come from short-term studies, it is important to review the evidence that current therapies provide long-term benefit.Method and resultsLong-term data from both registry studies and long-term follow-up studies, and efficacy treatment data were reviewed. Registry data show that the course of MS is predictable after a certain level of disability is reached, indicating that short-term efficacy data from randomized, controlled trials provide evidence of long-term benefit. Long-term studies of patients originally enrolled in pivotal randomized, controlled trials consistently show that delayed or discontinued treatment provides less benefit than continuous therapy. The 16-Year Long-Term Follow-Up Study of interferon beta-1b (IFNβ-1b; Betaferon®/Betaseron®) therapy had the highest ascertainment of long-term follow-up efforts of the pivotal trials, which led to the currently approved therapies. Disability scores at the start of treatment were predictive of their current disability scores. In addition, this 16-year study showed an excellent safety profile with no unexpected side effects to IFNβ-1b and a lower mortality rate after 16 years compared with those receiving placebo treatment during the pivotal study (6 deaths vs 20 deaths).ConclusionThis article reviews the key data and provides recommendations for optimizing clinical studies in MS to demonstrate long-term patient benefit.

AB - BackgroundThe therapeutic goal for multiple sclerosis (MS) is to achieve a better long-term outcome. However, since available data come from short-term studies, it is important to review the evidence that current therapies provide long-term benefit.Method and resultsLong-term data from both registry studies and long-term follow-up studies, and efficacy treatment data were reviewed. Registry data show that the course of MS is predictable after a certain level of disability is reached, indicating that short-term efficacy data from randomized, controlled trials provide evidence of long-term benefit. Long-term studies of patients originally enrolled in pivotal randomized, controlled trials consistently show that delayed or discontinued treatment provides less benefit than continuous therapy. The 16-Year Long-Term Follow-Up Study of interferon beta-1b (IFNβ-1b; Betaferon®/Betaseron®) therapy had the highest ascertainment of long-term follow-up efforts of the pivotal trials, which led to the currently approved therapies. Disability scores at the start of treatment were predictive of their current disability scores. In addition, this 16-year study showed an excellent safety profile with no unexpected side effects to IFNβ-1b and a lower mortality rate after 16 years compared with those receiving placebo treatment during the pivotal study (6 deaths vs 20 deaths).ConclusionThis article reviews the key data and provides recommendations for optimizing clinical studies in MS to demonstrate long-term patient benefit.

U2 - 10.1177/1352458509105426

DO - 10.1177/1352458509105426

M3 - Article

VL - 15

SP - 951

EP - 958

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 8

ER -